Preimplantation Genetic Testing Market Report 2026

The preimplantation genetic testing market size has grown rapidly in recent years. It will grow from $0.92 billion in 2025 to $1.03 billion in 2026 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to increasing utilization of assisted reproductive technologies, advancements in embryo biopsy techniques, growing awareness of genetic disease prevention, expansion of fertility clinics, improving IVF success outcomes.

The preimplantation genetic testing market size is expected to see rapid growth in the next few years. It will grow to $1.57 billion in 2030 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to increasing demand for personalized reproductive medicine, rising adoption of advanced genomic technologies, expansion of fertility preservation services, growing investment in reproductive health infrastructure, increasing regulatory acceptance of genetic screening. Major trends in the forecast period include increasing adoption of embryo screening procedures, rising use of next generation sequencing in ivf, expansion of genetic testing in fertility treatments, growing demand for improved implantation success rates, enhanced focus on reducing genetic disorders.

The increase in in vitro fertilization (IVF) procedures is anticipated to drive the growth of the preimplantation genetic testing market in the coming years. IVF involves fertilizing an egg with sperm outside the body to create an embryo, which is then transferred to the uterus. The expansion of IVF procedures is fueled by advancements in reproductive technology, rising infertility rates, and greater public awareness. The growth in IVF procedures is supporting the preimplantation genetic testing market by increasing the need for genetic screening of embryos prior to implantation. For example, in June 2025, the Human Fertilisation & Embryology Authority, a UK-based independent regulator of fertility treatment, reported that in 2023, 52,400 patients underwent more than 77,500 IVF cycles at licensed fertility clinics in the UK. Egg freezing cycles rose from 4,700 in 2022 to 6,900 in 2023, representing 7% of all cycles. Consequently, the rise in IVF procedures is propelling the preimplantation genetic testing market.

Major companies in the preimplantation genetic testing market are advancing next-generation sequencing (NGS) technologies to improve accuracy, efficiency, and speed in genetic screening, allowing for more comprehensive analysis and better-informed decisions for prospective parents. Next-generation sequencing (NGS) tools facilitate rapid, high-throughput analysis of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), providing detailed insights into genetic variations and gene expression, thereby enhancing accuracy and supporting personalized medicine. For example, in July 2023, Thermo Fisher Scientific, a U.S.-based biotechnology company, introduced the Ion ReproSeq PGT-A Kit and the Ion AmpliSeq Polyploidy Kit, advanced NGS tools aimed at improving IVF and ICSI research. These assays optimize workflows from sample processing to aneuploidy analysis using the Ion Torrent Genexus integrated sequencer, representing a notable advancement in the preimplantation genetic testing market by improving embryo screening and success rates in assisted reproductive technologies.

In April 2024, GenEmbryomics, an Australia-based provider of embryo genetic testing services, collaborated with Progenesis Inc. to provide comprehensive preimplantation genetic testing (PGT) services, including PGT-A, PGT-M, PGT-SR, and PGT-WGS. Through this partnership, the companies seek to make advanced embryo genetic testing more accessible to IVF clinics and patients, improving accuracy in embryo selection and supporting informed reproductive decisions. This collaboration underscores the market’s increasing focus on genome-wide screening and advanced reproductive genomics solutions. Progenesis Inc. is a U.S.-based laboratory specializing in IVF and PGT services.

Major companies operating in the preimplantation genetic testing market are Thermo Fisher Scientific, Abbott Laboratories, Laboratory Corporation of America Holdings, Agilent Technologies Inc., Illumina Inc., Revvity Health Science Inc., CooperSurgical Inc., Natera Inc., Myriad Genetics Inc., Fulgent Genetics Inc., Invitae Corporation, Takara Bio Inc., MedGenome Labs Ltd., Genea Limited, Ovation Fertility, Juno Genetics Ltd, Invicta Genetics, Progenesis, Bioarray SL, PacGenomics, Reproductive Genetic Innovations LLC, SEQUENCE46 LLC.

North America was the largest region in the preimplantation genetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preimplantation genetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the preimplantation genetic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the preimplantation genetic testing market by increasing costs of imported sequencing instruments, laboratory consumables, imaging systems, and genetic analysis software. Fertility centers and diagnostic laboratories in North America and Europe are most affected due to dependence on imported high-precision equipment, while Asia-Pacific faces cost pressures on expanding IVF services. These tariffs can raise treatment costs and limit patient access. However, they are also encouraging local manufacturing of diagnostic tools, regional reagent production, and technological innovation in cost-efficient genetic testing solutions.

The preimplantation genetic testing market research report is one of a series of new reports that provides preimplantation genetic testing market statistics, including preimplantation genetic testing industry global market size, regional shares, competitors with a preimplantation genetic testing market share, detailed preimplantation genetic testing market segments, market trends and opportunities, and any further data you may need to thrive in the preimplantation genetic testing industry. This preimplantation genetic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Preimplantation genetic testing (PGT) is a procedure that assesses embryos for genetic issues before implantation during in vitro fertilization (IVF). It aids in detecting genetic abnormalities to prevent certain inherited conditions, thereby increasing the chances of a successful pregnancy. PGT improves the likelihood of successful implantation, reduces the risk of miscarriage, and helps prevent genetic disorders.

The primary procedures for preimplantation genetic testing are preimplantation genetic screening and preimplantation genetic diagnosis. Preimplantation genetic screening (PGS) is a technique used in assisted reproduction to examine embryos for chromosomal abnormalities prior to implantation. The range of products includes reagents and consumables, instruments, and software utilized in various technologies such as next-generation sequencing (NGS), polymerase chain reaction (PCR), fluorescent in situ hybridization (FISH), and others. It is applied for a variety of purposes, including chromosomal abnormalities, aneuploidy screening, X-linked disorders, embryo testing, human leukocyte antigen (HLA) typing, and more, across different end users such as hospitals, fertility centers, diagnostic centers, research centers, and academic laboratories.

The preimplantation genetic testing (PGT) market consists of revenues earned by entities by providing services such as data analysis tools, genetic counseling, cloud-based platforms, and embryo selection algorithms. The market value includes the value of related goods sold by the service provider or included within the service offering. The preimplantation genetic testing (PGT) market also includes sales of genetic testing (PGT) kits, next-generation sequencers, and polymerase chain reaction (PCR) machines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.